Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies
Blood Adv
.
2021 Nov 23;5(22):4630-4633.
doi: 10.1182/bloodadvances.2021004190.
Authors
Samer Al Hadidi
1
2
,
Rammurti T Kamble
1
,
George Carrum
1
,
Helen E Heslop
1
3
,
Carlos Almeida Ramos
1
Affiliations
1
The Center for Cell and Gene Therapy, Department of Hematology and Oncology.
2
Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, AZ; and.
3
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX.
PMID:
34461636
PMCID:
PMC8759126
DOI:
10.1182/bloodadvances.2021004190
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Hematologic Neoplasms* / epidemiology
Hematologic Neoplasms* / therapy
Humans
Quality of Life*
Grants and funding
P30 CA125123/CA/NCI NIH HHS/United States
P50 CA126752/CA/NCI NIH HHS/United States
T32 HL092332/HL/NHLBI NIH HHS/United States